Nouscom – First Patient Dosed in a Phase 1 Trial with NOUS-209, an ‘off-the-shelf’ Neoantigen Cancer Vaccine, in MSI-High Solid Tumors

BASEL, Switzerland – 9 December 2019: Nouscom, an immuno-oncology company developing off-the-shelf and personalized cancer neoantigen vaccines, announced today that the first patient has been [...]